The consequences of the strict health restrictions during the first wave of COVID-19 on lung cancer (LC) patients are not known. This cohort study evaluated the impact of the initial lockdown on management of and long-term outcome in LC patients. This exposed–unexposed-type study included two evaluation periods of 6 months each in non-selected patients; one began on the first day of lockdown in 2020, and the other in 2019 during the same calendar period. Various indicators were compared: clinical profiles, management delays and overall survival beyond 2 years. A total of 816 patients from 7 public or private centers were enrolled. The clinical characteristics of the patients in 2020 did not differ from those in 2019, except that the population was older (p= 0.002) with more non-smokers (p= 0.006). Delays for pre-therapeutic medical management were generally reduced after the first imaging in 2020 (1.28 [1.1–1.49]). In the multivariate analysis, being part of the 2020 cohort was correlated with better prognosis (HR = 0.71 [0.5–0.84],p< 0.001). The gain observed in 2020 mainly benefited non-smoking patients, along with ECOG PS 0–2 (p= 0.01), stage 4 (p= 0.003), squamous cell carcinoma (p= 0.03) and receiving systemic therapy (p= 0.03). In conclusion, the first lockdown did not exert any deleterious impact on LC patients.
COVID-19第一波疫情期间严格的健康限制措施对肺癌患者的影响尚不明确。本队列研究评估了首次封锁对肺癌患者治疗管理及长期预后的影响。这项暴露-非暴露型研究纳入了未经筛选的患者，分别以2020年封锁首日及2019年相同日历时段为起点，对两个为期6个月的评估期进行比较。研究对比了多项指标：临床特征、治疗延迟情况及2年以上总生存期。共纳入来自7家公立或私立中心的816例患者。除2020年患者群体年龄更大（p=0.002）且非吸烟者比例更高（p=0.006）外，其临床特征与2019年无显著差异。2020年首次影像学检查后的治疗前医疗管理延迟普遍缩短（1.28[1.1-1.49]）。多变量分析显示，纳入2020年队列与更好的预后相关（HR=0.71[0.5-0.84]，p<0.001）。2020年观察到的生存获益主要惠及非吸烟患者，以及ECOG PS 0-2（p=0.01）、4期（p=0.003）、鳞状细胞癌（p=0.03）和接受全身治疗（p=0.03）的患者。综上所述，首次封锁未对肺癌患者产生不良影响。
肿瘤(癌症)患者之家